0RU5.L
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
Industry
Medical - Pharmaceuticals
IPO Date
2017-12-13
Stock Exchange
LSE
Ticker
0RU5.L
According to Oncoinvent ASA’s latest financial reports and current stock price. The company's current PE Ratio is -0.14. This represents a change of -89.97% compared to the average of -1.40 of the last 4 quarters.
The mean historical PE Ratio of Oncoinvent ASA over the last ten years is -6.88. The current -0.14 PE Ratio has changed 103.45% with respect to the historical average. Over the past ten years (40 quarters), 0RU5.L's PE Ratio was at its highest in in the June 2023 quarter at -0.06. The PE Ratio was at its lowest in in the December 2016 quarter at -11.14.
Average
-6.88
Median
-6.43
Minimum
-17.25
Maximum
-2.07
Discovering the peaks and valleys of Oncoinvent ASA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 40.64%
Maximum Annual PE Ratio = -2.07
Minimum Annual Increase = -61.99%
Minimum Annual PE Ratio = -17.25
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -2.07 | -8.59% |
| 2023 | -2.27 | 3.42% |
| 2022 | -2.19 | -61.99% |
| 2021 | -5.76 | -38.57% |
| 2020 | -9.38 | 32.42% |
| 2019 | -7.09 | -8.27% |
| 2018 | -7.73 | 40.64% |
| 2017 | -5.49 | -42.67% |
| 2016 | -9.58 | -44.45% |
| 2015 | -17.25 | -19.87% |
The current PE Ratio of Oncoinvent ASA (0RU5.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.18
5-year avg
-4.34
10-year avg
-6.88
Oncoinvent ASA’s PE Ratio is greater than Arecor Therapeutics plc (-3.75), less than Imugene Limited (0), greater than Yext, Inc. (-0.97), less than null (0), less than null (38.88),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.75 | N/A | |
| 0 | N/A | |
| -0.97 | $1.05B | |
| 0 | N/A | |
| 38.88 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncoinvent ASA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncoinvent ASA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oncoinvent ASA's PE Ratio?
How is the PE Ratio calculated for Oncoinvent ASA (0RU5.L)?
What is the highest PE Ratio for Oncoinvent ASA (0RU5.L)?
What is the 3-year average PE Ratio for Oncoinvent ASA (0RU5.L)?
What is the 5-year average PE Ratio for Oncoinvent ASA (0RU5.L)?
How does the current PE Ratio for Oncoinvent ASA (0RU5.L) compare to its historical average?